Aadi Bioscience (Aadi Bioscience) FCF Margin % : -165.35% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aadi Bioscience's Free Cash Flow for the three months ended in Dec. 2023 was $-10.46 Mil. Aadi Bioscience's Revenue for the three months ended in Dec. 2023 was $6.33 Mil. Therefore, Aadi Bioscience's FCF Margin % for the quarter that ended in Dec. 2023 was -165.35%.

As of today, Aadi Bioscience's current FCF Yield % is -128.29%.

The historical rank and industry rank for Aadi Bioscience's FCF Margin % or its related term are showing as below:

AADI' s FCF Margin % Range Over the Past 10 Years
Min: -2246.9 Med: -295.22 Max: -90.72
Current: -261.29

During the past 4 years, the highest FCF Margin % of Aadi Bioscience was -90.72%. The lowest was -2246.90%. And the median was -295.22%.

AADI's FCF Margin % is ranked worse than
57.63% of 1036 companies
in the Biotechnology industry
Industry Median: -148.935 vs AADI: -261.29

Aadi Bioscience FCF Margin % Historical Data

The historical data trend for Aadi Bioscience's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience FCF Margin % Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-90.72

-2,246.90

-329.15

-261.29

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial									-217.87	-386.55	-281.31	-218.98	-165.35

Competitive Comparison of Aadi Bioscience's FCF Margin %

For the Biotechnology subindustry, Aadi Bioscience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's FCF Margin % falls into.

Aadi Bioscience FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aadi Bioscience's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-63.635	/	24.354
	=	-261.29 %

Aadi Bioscience's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-10.46	/	6.326
	=	-165.35 %

Aadi Bioscience FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (Aadi Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (NAS:AADI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Executives

Neil Desai	director, officer: See Remarks	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
David James Lennon	director, officer: Chief Executive Officer	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Scott M. Giacobello	officer: Chief Financial Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Lorettta M Itri	officer: Chief Medical Officer
Brendan Delaney	officer: Chief Operating Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun	director	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault	officer: Chief Financial Officer
Behzad Aghazadeh	director, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc	director, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc	director, other: See Remarks	110 GREEN STREET, SUITE 800, NEW YORK NY 10012